When Don Mattrick took over as Chief Executive at social-gaming company Zynga Inc. 16 months ago, it’s fair to say he was joining a business that was at a crossroads. Mattrick replaced Zynga Inc (NASDAQ:ZNGA)’s founder and CEO Mark Pincus at a time when the company was in the middle of a restructuring, had recently reported a decline in sales, was starting to focus more on mobile games, and had seen its stock price fall about 70% since it went public in December 2011 at $10 a share. Zynga Inc (NASDAQ:ZNGA) belongs to Technology sector. Its net profit margin is -21.30% and weekly performance is 1.25%. On last trading day company shares ended up $2.43. Zynga Inc (NASDAQ:ZNGA) distance from 50-day simple moving average (SMA50) is -10.23%. Quest Diagnostics (NYSE:DGX), announced BRCAvantage Plus, the company's first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA as well as BRCA genes. The new service is now available in all 50 states. Quest Diagnostics Inc. (NYSE:DGX) shares decreased -1.21% in last trading session and ended the day at $61.36. DGX Gross Margin is 38.60% and its return on assets is 5.30%. Quest Diagnostics Inc. (NYSE:DGX) quarterly performance is 2.13%. On Oct 28, Fonar Corporation (NASDAQ:FONR), announced a sale of its UPRIGHT® MRI to a long-time FONAR customer, Medserena, of Germany. The FONAR UPRIGHT® Multi-Position MRI (aka Stand-Up® MRI) scanner is the world's only MRI scanner licensed under FONAR's multiple UPRIGHT® MRI patents to scan all the patient's body parts in their normal multiple, full weight-bearing UPRIGHT® positions. This will be the fifth sale of a FONAR UPRIGHT MRI in Germany. On 04 November, Fonar Corp. (NASDAQ:FONR) shares moved up 3.39% and was closed at $12.80. FONR EPS growth in last 5 year was 48.30%. Fonar Corp. (NASDAQ:FONR) year to date (YTD) performance is -39.65%. Amgen Inc. (NASDAQ:AMGN) said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group. Amgen Inc. (NASDAQ:AMGN) ended the last trading day at $160.41. Company weekly volatility is calculated as 1.89% and price to cash ratio as 4.35. Amgen Inc. (NASDAQ:AMGN) showed a weekly performance of 2.05%. On Oct 27, Goody’s® Powder, part of the Prestige Brands Holdings, Inc. (NYSE:PBH) portfolio, announced that it is expanding its partnership with Dale Earnhardt Jr., the most popular driver in NASCAR. After the announcement, which was made at the Goody's® Headache Relief Shot® 500 at Martinsville Speedway, Earnhardt went on to win the race. Prestige Brands Holdings, Inc. (NYSE:PBH) shares decreased -0.56% in last trading session and ended the day at $35.53. PBH Gross Margin is 56.00% and its return on assets is 3.70%. Prestige Brands Holdings, Inc. (NYSE:PBH) quarterly performance is 14.91%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
